Antagonism of the renin-angiotensin system: ACE-inhibitors and angiotensin-II-receptor antagonists;Blockade des Renin-Angiotensin-Systems: ACE-Hemmer und Angiotensin-II-Rezeptorblocker

Wiener Medizinische Wochenschrift

Volumn 146, Issue 11, 1996, Pages 228-231

  Pichler, M ^a   Klein, W ^a   Huber, K ^a   Pachinger, O ^a  

^a Rehabilitationszentrum Grossgmain ^*

Author keywords

ACE inhibitors; hypertension; losartan; renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; ESSENTIAL HYPERTENSION; FLUID BALANCE; HUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETIC NEPHROPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 0029951241     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Awan NA, Mason DT: Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J 1996;131:177-185.
2. Bönner G: Haben die Kinine eine Bedeutung für die antihypertensive Wirkung der ACE-Hemmer? Z Kardiol 1988;77 (suppl): 23-27.
3. Bönner G, Rahn KH: ACE-Hemmer Handbuch. Stuttgart, Schattauer, 1994.
4. Burton J, Cody RJ, Herd JA, et al: Specific inhibition of Renin by an Angiotensinogen Analog: Studies in Sodium Depletion and Renin-Dependent Hypertension. Proc Natl Acad Sci USA 1980;77:5476-5479.
5. Crozier I., Ikram H., Awan N., et al for the Losartan Hemodynamic Study Group: Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
6. Dahlöf B: Efficay and tolerability of losartan potossium and atenolol in patients with mild to moderate essential hypertension. Am Heart J 1995;8:578-583.
7. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77 (suppl I): 4-13.
8. Goldberg A, Dunlay M, Sweet C: Safety and Tolerabilily of Losartan Potassium, an Angiotensin II Receptor Antagonist. Compared with Hydrochlorothiazide, Atenolol, Felodipine ER, and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Systemic Hypertension. Am J Cardiol 1995;75:793-795.
9. Goldberg MR: Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients. Hypertension 1995;25:37-46.
10. Goldberg MR: Effects of Losartan on Blood Pressure, Plasma Renin Activity, and Angiotensin II in Volunteers. Hypertension 1993;21:704-713.
11. Gradman AH, Arcuri EK, Goldberg A, et al: A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared with Enalapril Maleate in Patients with Essential Hypertension. Hypertension 1995;25:1345-1350.
12. Grobecker H: Pharmakologie und klinische Pharmakologie von Hemmstoffen des Angiotensin-Konversionsenzyms (ACE-Inhibitoren). Herz Kreisl 1992;24:331-341 und 372-382.
13. Johnston CI: Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-1407.
14. Kang PM, Landau AJ, Eberhardt RT, Frishman WH: Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am Heart J 1994;127:1388-1401.
15. Kleinert HD: Renin Inhibition. Cardiovasc Drugs Ther 1995;9:645-655.
16. Lacourciere Y, Brunner H, Irwin R, Karlberg B, et al: Effects of modulators of the renin-angiotensin-aldosteron system on cough. J Hypertens 1994;12:1381-1397.
17. Lang ML, Yellen LG, McKelvie RS, et al on behalf of the Losartan Pilot Exercise Study Investigators: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure (abstr.). Circulation 1994;90:1602.
18. Linz W, Martorana PA, Schölkens B: Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc. Pharmacol 1990: 15 (suppl 6): 99-109.
19. Losartan for Hypertension: Medical Letter, 1995; 37, June 23.
20. MacFadyen RJ, Reid JL: Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994;12:1333-1338.
21. MacKay JH, Arcuri KE, Goldberg AI, et al: Losartan and low-dose Hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996;156:278-285.
22. Madwed JB, Winquist RJ: Effects of Losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine. J Hypertens 1994;12:159-162.
23. Mann J: Angiotensin-Rezeptor-Antagonisten. Eine neue Klasse von Antihypertonika. Dtsch Med Wschr 1996;121:568-571.
24. Maschio G, Alberti D, Janin G, et al: Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. N Engl J Med 1996;334:939-945.
25. Nelson E, Merril D: Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist in essential hypertension. J Hypertens 1991;9:468-469.
26. Ohtawa M, Takayama F, Saitoh K, et al: Pharmakokinetics and biochemical efficacy after single and multiple administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharm 1993;35:290-297.
27. Opie LH: Angiotensin Converting Enzyme Inhibitors. 1-19, Wiley-Liss, 1994.
28. Pitt B, Chang P, Timmermann P: Angiotensin II Receptor Antagonists in Heart Failure: Rationale and Design of the Evaluation of Losartan in the Elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;9:693-700.
29. Streeten DH, Anderson GH, Freiberg JM, Dalakos TG: Use of angiotensin II antagonist (saralosin) in recognition of "angiotensinogenic" hypertension. N Engl J Med 1975;292:657-662.
30. Sweet CS, Rucinska EJ: Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994 (suppl D): D139-D144.
31. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
32. Timmermans P, Carini DJ, Chiu AT, et al: The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991;4:275-281.
33. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
34. Weber MA, Byyny RL, Prott JH, et al: Blood Pressure Effects of the Angiotensin II Receptor Blocker, Losartan. Arch Intern Med 1995;155:405-411.
35. Weir MR: Pharmacologic Antagonism of the Renin-Angiotensin-Aldosterone System: A Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists. Cardiovasc Rev Reports 1995;16:37-42.